IL289456A - Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds - Google Patents

Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds

Info

Publication number
IL289456A
IL289456A IL289456A IL28945621A IL289456A IL 289456 A IL289456 A IL 289456A IL 289456 A IL289456 A IL 289456A IL 28945621 A IL28945621 A IL 28945621A IL 289456 A IL289456 A IL 289456A
Authority
IL
Israel
Prior art keywords
dihydropyrido
oxo
pyrimidine compounds
compounds inhibit
inhibit eif4e
Prior art date
Application number
IL289456A
Other languages
English (en)
Hebrew (he)
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Publication of IL289456A publication Critical patent/IL289456A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL289456A 2019-07-02 2021-12-28 Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds IL289456A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962869662P 2019-07-02 2019-07-02
PCT/US2020/040299 WO2021003157A1 (en) 2019-07-02 2020-06-30 Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
IL289456A true IL289456A (en) 2022-02-01

Family

ID=71614984

Family Applications (1)

Application Number Title Priority Date Filing Date
IL289456A IL289456A (en) 2019-07-02 2021-12-28 Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds

Country Status (15)

Country Link
US (2) US11286268B1 (cg-RX-API-DMAC10.html)
EP (1) EP3994139A1 (cg-RX-API-DMAC10.html)
JP (1) JP7595055B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220061945A (cg-RX-API-DMAC10.html)
CN (1) CN114269756B (cg-RX-API-DMAC10.html)
AR (1) AR119339A1 (cg-RX-API-DMAC10.html)
AU (1) AU2020299362B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021026682A2 (cg-RX-API-DMAC10.html)
CA (2) CA3188446A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021003573A1 (cg-RX-API-DMAC10.html)
IL (1) IL289456A (cg-RX-API-DMAC10.html)
PY (1) PY2031844A (cg-RX-API-DMAC10.html)
TW (1) TWI748541B (cg-RX-API-DMAC10.html)
UY (1) UY38773A (cg-RX-API-DMAC10.html)
WO (1) WO2021003157A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378821A1 (en) * 2019-07-02 2022-12-01 Effector Therapeutics, Inc. Methods of treating braf-mutated cancer cells
EP4076438A4 (en) * 2019-12-18 2023-11-29 Merck Sharp & Dohme LLC BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HERPES VIRUSES
WO2021240337A1 (en) * 2020-05-27 2021-12-02 Effector Therapeutics, Inc. Covalent modifiers of eif4e inhibiting compounds
KR20230124648A (ko) * 2020-12-22 2023-08-25 화이자 인코포레이티드 Eif4e 억제제의 고체 형태
EP4430029A4 (en) * 2021-11-09 2025-09-10 Vigil Neuroscience Inc HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 AND METHODS OF USE
AU2023375677A1 (en) * 2022-11-10 2025-06-05 Ribometrix, Inc. COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF
TW202428278A (zh) * 2022-12-23 2024-07-16 大陸商南京聖和藥業股份有限公司 作為eIF4E抑制劑的化合物及其應用
IL326137A (en) 2023-07-28 2026-03-01 Cogent Biosciences Inc PI3K inhibitors
WO2025101516A1 (en) * 2023-11-06 2025-05-15 Ribometrix, Inc. Methods of using eif4e inhibitors for treating cancer
WO2025120599A1 (en) * 2023-12-08 2025-06-12 Ribometrix, Inc. METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCER

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255161A1 (en) 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
CA2724426A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
US9540371B2 (en) 2013-04-29 2017-01-10 Vanderbilt University Substituted quinazolin-4(3H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, pyrido[3,2-d]pyrimidin-4(3H)-ones and pyrido[2,3-d]pyrimidin-4(3H)-ones as positive allosteric modulators of muscarinic acetycholine receptor M1
JP2017510552A (ja) 2014-02-07 2017-04-13 イーフェクター セラピューティクス, インコーポレイテッド 線維性疾患を治療するための方法
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 MnK抑制劑及其相關方法

Also Published As

Publication number Publication date
CA3188446A1 (en) 2021-01-07
JP7595055B2 (ja) 2024-12-05
US20230108594A1 (en) 2023-04-06
PY2031844A (es) 2021-04-19
CN114269756A (zh) 2022-04-01
CA3085255A1 (en) 2021-01-02
TW202115058A (zh) 2021-04-16
AR119339A1 (es) 2021-12-09
KR20220061945A (ko) 2022-05-13
TWI748541B (zh) 2021-12-01
WO2021003157A1 (en) 2021-01-07
UY38773A (es) 2021-01-29
AU2020299362A1 (en) 2022-02-24
US11286268B1 (en) 2022-03-29
AU2020299362B2 (en) 2026-02-26
CL2021003573A1 (es) 2022-08-12
BR112021026682A2 (pt) 2022-03-15
EP3994139A1 (en) 2022-05-11
JP2022539256A (ja) 2022-09-07
CN114269756B (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
HUE071131T2 (hu) Helyettesített 1,2-dihidro-3H-pirazolo[3,4-d]pirimidin-3-on-származékok
HUE051424T2 (hu) RET kináz inhibitor szubsztituált pirazolo[1,5-a]piridin vegyületek
EP4037688A4 (en) ANTIVIRAL HETEROCYCLIC COMPOUNDS
DK3523302T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
EP3980010A4 (en) 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS
IL256898B (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
DK3583105T3 (da) Pyrrol[1,2-b]pyridazinderivater
LT3555097T (lt) Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
PL3345907T3 (pl) Związki pirazolo[3,4-d]pirymidynowe lub ich sole
HRP20171599T2 (hr) DERIVATI PIROLO[2,3-d]PIRIMIDINA KAO INHIBITORI JANUS KINAZA (JAK)
IL282740B2 (en) 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-H1-pyrido[3,2-d]pyrimidine-2,4-dione
IL258231A (en) New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
LT3483163T (lt) Triazol[4,5-d]pirimidino dariniai kaip cb2 receptorių antagonistai
IL284767A (en) Heterocyclic compounds as adenosine antagonists
EP3744723A4 (en) SUBSTITUTED MACROCYCLIC PYRAZOLO [1,5-A] PYRIMIDINE COMPOUND
EP3508487A4 (en) PYRAZOLO [1,5-A] PYRIMIDINE COMPOUND
LT3820872T (lt) Pirolo[1,2-b]piridazino dariniai
EP3096762C0 (en) PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL COMPOUNDS
ZA202004352B (en) Amidine substituted benzoyl derivatives useful as herbicides
IL284762A (en) Heterocyclic compounds as adenosine antagonists
MA54960A (fr) Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine
EP3330271A4 (en) PYRROLO [2,3-D] PYRIMIDINE COMPOUND OR SALT THEREOF
HUE052997T2 (hu) JAK kináz inhibitor pirazol[1,5-a]pirimidin származékok
HK40064784A (en) Heterocyclic compounds as adenosine antagonists
HK40077793A (en) Antiviral heterocyclic compounds